Seelos Therapeutics Inc. (SEEL)
Seelos Therapeutics Statistics
Share Statistics
Seelos Therapeutics has 581K shares outstanding. The number of shares has increased by -79.68% in one year.
| Shares Outstanding | 581K |
| Shares Change (YoY) | -79.68% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 370.48K |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -22.85 and the forward PE ratio is null. Seelos Therapeutics's PEG ratio is 0.36.
| PE Ratio | -22.85 |
| Forward PE | n/a |
| PS Ratio | 392.91 |
| Forward PS | n/a |
| PB Ratio | -25.83 |
| P/FCF Ratio | -36.2 |
| PEG Ratio | 0.36 |
Enterprise Valuation
Seelos Therapeutics has an Enterprise Value (EV) of 876.81M.
| EV / Sales | 398.01 |
| EV / EBITDA | -23.23 |
| EV / EBIT | -36.67 |
| EV / FCF | -36.67 |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of -0.42.
| Current Ratio | 0.14 |
| Quick Ratio | 0.14 |
| Debt / Equity | -0.42 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.6 |
| Interest Coverage | -539.99 |
Financial Efficiency
Return on Equity is 113.05% and Return on Invested Capital is 209.87%.
| Return on Equity | 113.05% |
| Return on Assets | -699.19% |
| Return on Invested Capital | 209.87% |
| Revenue Per Employee | $275.38K |
| Profits Per Employee | $-4.74M |
| Employee Count | 8 |
| Asset Turnover | 0.41 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.94, so Seelos Therapeutics's price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 22.56 |
| Relative Strength Index (RSI) | 31.71 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Seelos Therapeutics had revenue of 2.2M and earned -37.88M in profits. Earnings per share was -7.73.
| Revenue | 2.2M |
| Gross Profit | -27.91M |
| Operating Income | -40.5M |
| Net Income | -37.88M |
| EBITDA | -37.75M |
| EBIT | -37.81M |
| Earnings Per Share (EPS) | -7.73 |
Balance Sheet
The company has 3M in cash and 14.23M in debt, giving a net cash position of -11.23M.
| Cash & Cash Equivalents | 3M |
| Total Debt | 14.23M |
| Net Cash | -11.23M |
| Retained Earnings | -252.63M |
| Total Assets | 2.38M |
| Working Capital | -28.18M |
Cash Flow
In the last 12 months, operating cash flow was -23.91M and capital expenditures 0, giving a free cash flow of -23.91M.
| Operating Cash Flow | -23.91M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.91M |
| FCF Per Share | -4.88 |
Margins
Gross margin is -1267.09%, with operating and profit margins of -1838.36% and -1719.56%.
| Gross Margin | -1267.09% |
| Operating Margin | -1838.36% |
| Pretax Margin | -1719.56% |
| Profit Margin | -1719.56% |
| EBITDA Margin | -1713.57% |
| EBIT Margin | -1838.36% |
| FCF Margin | -1085.43% |
Dividends & Yields
SEEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.38% |
| FCF Yield | -2.76% |
Analyst Forecast
Currently there are no analyst rating for SEEL.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 16, 2024. It was a backward split with a ratio of 1:8.
| Last Split Date | May 16, 2024 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -156.64 |
| Piotroski F-Score | 5 |